News Quantified

GLMD – galmed pharmaceuticals ltd. - ordinary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers

Galmed Pharmaceuticals Ltd. Unlocks CNS Potential with New Brain-Penetrating Aramchol Formulation [TheStreet.com]

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 [TheStreet.com]

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Form 6-K Galmed Pharmaceuticals For: Apr 14

Form 6-K Galmed Pharmaceuticals For: Apr 09

Form EFFECT Galmed Pharmaceuticals

Form POS AM Galmed Pharmaceuticals

Form 20-F Galmed Pharmaceuticals For: Dec 31

Top News Gainers

12/2 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) is now covered by analysts at Canaccord Genuity. They set a "buy" rating on the stock. 29.3%

3/18 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 18.0%

3/13 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its price target lowered by analysts at B. Riley from $28.00 to $11.00. They now have a "buy" rating on the stock. 13.2%

10/31 Galmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019 13.1%

1/7 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was upgraded by analysts at ValuEngine from a "buy" rating to a "strong-buy" rating. 11.9%

2/4 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $18.00 price target on the stock. 11.9%

1/4 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.3%

11/10 Edited Transcript of GLMD earnings conference call or presentation 6-Nov-19 1:30pm GMT [Yahoo! Finance News] 5.7%

8/5 Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.4%

8/6 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $20.00 price target on the stock. 3.9%

Top News Decliners

3/12 Q4/2019 12/31/2019 EPS -0.390 ZacksConsensus -0.370 ActVsEst (0.020) - Miss -19.5%

8/5 Form 6-K Galmed Pharmaceuticals For: Jun 30 -17.8%

7/22 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) is now covered by analysts at Laidlaw. They set a "buy" rating on the stock. -11.7%

2/6 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.50 price target on the stock. -11.1%

1/30 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $14.00 price target on the stock, down previously from $59.00. -11.1%

11/6 Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results -11.0%

10/23 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.50 price target on the stock. -8.0%

5/7 Q1/2019 3/31/2019 EPS -0.170 ZacksConsensus -0.190 ActVsEst 0.020 - Beat -7.7%

3/5 Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results and Provide Business Update on Thursday March 12 -6.2%

3/17 Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. -5.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day